Previous 10 | Next 10 |
home / stock / ipsef / ipsef news
Ipsen e xtends e xpiration d ate of t ender o ffer for Albireo Pharma , Inc. to 1 March 202 3 Extension a llows for the satisfaction of the HSR Act related condition as o utlined ...
Ipsen, Université de Montréal and IRICoR broaden existing oncology partnership, with an exclusive licens e agreement and two new discovery-stage programs Ipsen will now lead all development and commercialization activities of the licensed asset ...
Three-year data – with a median follow-up of 44 months – from the Phase III CheckMate -9ER trial demonstrate maintained overall survival benefits with Cabometyx plus nivolumab compared to sunitinib regardless of IMDC risk score 1 Data represent the longest reported follow-up...
Ipsen S.A. (IPSEY) Q4 2022 Results Conference Call February 09, 2023 07:45 AM ET Company Participants David Loew - CEO Aymeric Le Chatelier - CFO Howard Mayer - Head, Research and Development Conference Call Participants Elizabeth Walton - Credit Suisse ...
2022 total sales up by 8.5% at CER 1 (14.4% as reported) with growth platforms’ 2 sales increasing by 20.9% 1 and Somatuline ® (lanreotide) sales declining by 5.6% 1 2022 core operating margin of 36.9%, broadly in line with 2021; IFRS operating margin of 24.1%,...
Summary The backbone of the Albireo is Bylvay, a product in a platform already approved in one indication and expected to be approved in two significant larger indications. Ipsen recognizes the huge potential and is offering $42 plus a $10 CVR to acquire Albireo. The deal is expected to...
Summary Albireo, Mirum Pharmaceuticals, Inc.'s only competitor in a billion-dollar market, is being acquired by Ipsen for up to $1.2 billion. The biggest value driver of Mirum is Livmarli, currently the only approved life-saving product in a rare pediatric disease market worth $500 mill...
Ipsen to request re-examination of CHMP opinion on palovarotene as a potential treatment for fibrodysplasia ossificans progressiva in E.U. FOP is an ultra-rare disease that continuously and permanently causes abnormal bone formation. 1 There are currently no disease-modifying treatment op...
Investigational Onivyde ® (irinotecan liposome injection) in the NALIRIFOX treatment regimen demonstrated statistically significant improvements in overall survival and progression-free survival compared to nab-paclitaxel plus gemcitabine with a manageable safety profile 1 Result...
Transaction focused on Bylvay ® (odevixibat), the first-approved treatment in progressive familial intrahepatic cholestasis in U.S. and E.U., with potential in other rare diseases Acquisition aligned with Ipsen’s long-term strategy for expanding the scope of its Rare Disease p...
News, Short Squeeze, Breakout and More Instantly...
Ipsen Sa Ord Company Name:
IPSEF Stock Symbol:
OTCMKTS Market:
Decision adds to existing collaboration agreement with Exelixis, permitting Ipsen to seek potential marketing authorizations for Cabometyx ® (cabozantinib) in advanced pancreatic and extra pancreatic neuroendocrine tumors outside of the U.S. and Japan Agreemen...
Iqirvo ® (elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver disease called primary biliary cholangitis Approval based on positive Phase III ELATIVE trial data Primary biliary cholan...
Using Marengo’s TriSTAR platform, Ipsen and Marengo teams expand their ongoing oncology research to include up to two additional assets in new early development collaboration Research will focus on using Marengo’s TriSTAR platform to reinvigorate and mobilize selective V...